T1	Participants 39 119	previously treated patients with refractory advanced non-small-cell lung cancer:
T2	Participants 374 446	patients with locally advanced or metastatic non-small-cell lung cancer.
T3	Participants 455 542	1692 patients who were refractory to or intolerant of their latest chemotherapy regimen
T4	Participants 942 996	1129 patients were assigned gefitinib and 563 placebo.
T5	Participants 1236 1268	812 patients with adenocarcinoma
T6	Participants 1440 1453	never-smokers
T7	Participants 1540 1552	Asian origin
T8	Participants 1929 1972	never-smokers and patients of Asian origin.
